Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Earnings season begins this week. With the tariff overhang and higher expectations for coming quarters, forward earnings guidance from management will be crucial.

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 14 trades. If we ...

26 analysts have shared their evaluations of Regeneron Pharmaceuticals REGN during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a ...

Wall Street expects a year-over-year decline in earnings on higher revenues when United Airlines (UAL) reports results for the quarter ended June 2025. While this widely-known consensus outlook is ...

The big-bank earnings reports due this week mark the quasi-official start to the second-quarter earnings season. Analysts ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

It may be a year later than originally planned, but Regeneron Pharmaceuticals Inc. is set to commercialize Lynozyfic (linvoseltamab) in the U.S. following FDA approval for use in adults with relapsed ...